AUROBINDO PHARMA
|
|
BOM : 524804     NSE : AUROPHARMA     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Good [Stock is Cheap] Debt : Average |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
Jul 01,2022 |
Price(EOD): ₹ 522.55
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 30,616.20 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
AUROBINDO PHARMA | 0.2% | -1.9% | -46.9% |
SUN PHARMACEUTICAL INDUSTRIES | -1.1% | -3.8% | 22.7% |
DIVIS LABORATORIES | -1.1% | 3.1% | -14.6% |
DR REDDYS LABORATORIES | 1.6% | 1.2% | -17.2% |
CIPLA | 1.9% | -3.8% | -6.5% |
GLAND PHARMA | -0.1% | -6.5% | -20.6% |
PIRAMAL ENTERPRISES | 0.3% | -8% | -31.3% |
CADILA HEALTHCARE | 2.3% | -0.8% | -44.3% |
TORRENT PHARMACEUTICALS | 1.9% | 3.6% | -2.1% |
FUNDAMENTAL ANALYSIS OF AUROBINDO PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AUROBINDO PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
5.74
P/E Calculated based on EPS of 91.05
[ Mar2021 - Consolidated Results ] 1.4
P/B Calculated based on Book Value of 374.29
[ Mar2021 - Consolidated Results ] 1.31
P/S Calculated based on Revenues of 23455.5 Cr
[ TTM - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-36% -38% -23% |
SHARE PRICE MOMENTUM OF AUROBINDO PHARMA
AUROBINDO PHARMA vs SENSEX
DEBT OF AUROBINDO PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2021 2020 2019 Avg_3yrs |
0.25 0.29 0.4 0.31 |
0.23 0.33 0.5 0.35 |
[Last Annual Data : Mar2021]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF AUROBINDO PHARMA
Pledged Promoter Shares |
14.05 % | |
---|---|---|
As on : Mar2022 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF AUROBINDO PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-3.21% -4.12% -25.36% -5.09% |
-3.2% -23.56% -44.1% -28.32% |
QtrlyTrend |
-8 | |
Latest Qtr: Mar2022 | ||
Quarterly Result Analysis → |
AUROBINDO PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE DIVIDEND STABILITY | 1.8% | -5.2% | -3.5% |
S&P BSE 400 MIDSMALLCAP | 0.9% | -6% | -2.4% |
S&P BSE 150 MIDCAP | 0.8% | -5.7% | -1.7% |
S&P BSE ALLCAP | 0.6% | -4.9% | -0.8% |
S&P BSE 500 | 0.6% | -4.9% | -1% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY 500 VALUE 50 | 3.4% | -7.2% | -0.1% |
NIFTY MIDCAP150 | 1% | -5.4% | -1.1% |
NIFTY MID SMALL400 | 0.9% | -6% | -1.9% |
NIFTY LARGE MIDCAP 250 | 0.7% | -5% | -0.9% |
NIFTY PHARMA | 0.7% | -1.5% | -13.9% |
You may also like the below Video Courses
FAQ about AUROBINDO PHARMA
Is AUROBINDO PHARMA good for long term investment?
As on Jul 01,2022, the Fundamentals of AUROBINDO PHARMA look Strong and hence it may be good for long term investment! See Financial Performance of AUROBINDO PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AUROBINDO PHARMA UnderValued or OverValued?
As on Jul 01,2022, AUROBINDO PHARMA is Under Valued based on the estimates of intrinsic value and hence may be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of AUROBINDO PHARMA ?
As on Jul 01,2022, the Intrinsic Value of AUROBINDO PHARMA is Rs. 820.24 determined based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 820.24
Fair Value [Median EV / Sales Model] : Rs. 841.27
Fair Value [Median Price / Sales Model] : Rs. 678.41
Median Fair Value of AUROBINDO PHARMA : Rs. 820.24
Is AUROBINDO PHARMA trading at a Premium or Discount?
As on Jul 01,2022, AUROBINDO PHARMA is trading at a Discount of -36% based on the estimates of Median Intrinsic Value!SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs DR REDDYS LABORATORIES LTD
CIPLA LTD vs GLAND PHARMA LTD vs PIRAMAL ENTERPRISES LTD
CADILA HEALTHCARE LTD vs TORRENT PHARMACEUTICALS LTD vs ALKEM LABORATORIES LTD
LUPIN LTD vs AUROBINDO PHARMA LTD vs BIOCON LTD
ABBOTT INDIA LTD vs LAURUS LABS LTD vs IPCA LABORATORIES LTD
